Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Lipids in Health and Disease|September 30, 2015
Feeding butter with elevated content of trans-10, cis-12 conjugated linoleic acid to obese-prone rats impairs glucose and insulin toleranceMelissa Hamilton, Loren E Hopkins, Ousama AlZahal, et al.
Plos One|January 27, 2018
Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approachXiaoyan Li, Allison Keshishian, Melissa Hamilton, et al.
Human Gene Therapy|May 6, 2005
Periocular gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization in a human-sized eyeYoshitsugu Saishin, Raquel Lima Silva, Yumiko Saishin, et al.
Thrombosis and Haemostasis|March 17, 2017
Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. A propensity-matched analysis of 76,940 patientsXiaoyan Shawn Li, Steve Deitelzweig, Allison Keshishian, et al.
Stroke|December 21, 2018
Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation PatientsGregory Y H Lip, Allison Keshishian, Xiaoyan Li, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 2, 2008
Persistent expression of PEDF in the eye using high-capacity adenovectorsPing Chen, Melissa Hamilton, Charles A Thomas, et al.
Thrombosis and Haemostasis|October 26, 2018
Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical PracticeDerek Weycker, Xiaoyan Li, Gail DeVecchis Wygant, et al.
The Lancet. Oncology|January 15, 2022
Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trialDavid Cella, Robert J Motzer, Cristina Suarez, et al.
European Urology Oncology|March 15, 2022
Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 TrialJohannes Alfred Witjes, Matthew D Galsky, Jürgen E Gschwend, et al.
Plos One|April 13, 2012
Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responsesJoseph T Bruder, Elena Semenova, Ping Chen, et al.
Pageof 4